Abstract
Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients.
Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1).
Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group).
Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.
Keywords: Alternative therapy, Epilepsy, Long-term study, Neurosurgery, Pharmacoresistance, Vagus nerve stimulation, Neurological Disorder, Antilepitic Drugs, Antilepitic effect, Rationale, Dosing, Epileptic Patient, Aetiologies, Epileptic Seizures, Lennox Gastaut syndrome lepsy
Letters in Drug Design & Discovery
Title: Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy: A 15-Year Experience in an Italian Tertiary – Care Epilepsy Center
Volume: 8 Issue: 4
Author(s): Chiara Pizzanelli, Renato Galli, Filippo S. Giorgi, Alfonso Iudice, Enrica Bonanni, Veronica Pelliccia, Stella Jensen, Laura Manca, Bruno Lenzi, Ludovico Lutzemberger, Giuliano Parenti, Francesco Fornai and Luigi Murri
Affiliation:
Keywords: Alternative therapy, Epilepsy, Long-term study, Neurosurgery, Pharmacoresistance, Vagus nerve stimulation, Neurological Disorder, Antilepitic Drugs, Antilepitic effect, Rationale, Dosing, Epileptic Patient, Aetiologies, Epileptic Seizures, Lennox Gastaut syndrome lepsy
Abstract: Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients.
Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1).
Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group).
Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.
Export Options
About this article
Cite this article as:
Pizzanelli Chiara, Galli Renato, S. Giorgi Filippo, Iudice Alfonso, Bonanni Enrica, Pelliccia Veronica, Jensen Stella, Manca Laura, Lenzi Bruno, Lutzemberger Ludovico, Parenti Giuliano, Fornai Francesco and Murri Luigi, Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy: A 15-Year Experience in an Italian Tertiary – Care Epilepsy Center, Letters in Drug Design & Discovery 2011; 8 (4) . https://dx.doi.org/10.2174/157018011794839394
DOI https://dx.doi.org/10.2174/157018011794839394 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obituary
Mini-Reviews in Medicinal Chemistry A Comparative Study of the CYP450 Inhibition Potential of Marketed Drugs Using Two Fluorescence Based Assay Platforms Routinely Used in the Pharmaceutical Industry
Drug Metabolism Letters Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Diagnostic Biomarkers of Epilepsy
Current Pharmaceutical Biotechnology Study of Some Piperine Analogues on Drugs Efflux by Targeting P-glycoprotein, an in silico Approach
Letters in Drug Design & Discovery Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry Therapeutic Indications and Action Mechanisms of Bilirubin: Suggestions from Natural Calculus Bovis
Current Signal Transduction Therapy Animal Models of Narcolepsy
CNS & Neurological Disorders - Drug Targets Xenobiotic Acyl Glucuronides and Acyl CoA Thioesters as Protein- Reactive Metabolites With the Potential to Cause Idiosyncratic Drug Reactions
Current Drug Metabolism Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Biomedical Applications of Nanomaterials as Therapeutics
Current Medicinal Chemistry Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Potential Biomarkers with Plasma Cortisol, Brain-derived Neurotrophic Factor and Nitrites in Patients with Acute Ischemic Stroke
Current Neurovascular Research Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph
Anti-Cancer Agents in Medicinal Chemistry Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Interleukin-1β Increases Release of Endothelin-1 and Tumor Necrosis Factor as Well as Reactive Oxygen Species by Peripheral Leukocytes During Experimental Subarachnoid Hemorrhage
Current Neurovascular Research Recent Advances in Non-Perturbative Detection of Electric and Magnetic Fields for Physiological Monitoring
Recent Patents on Biomedical Engineering (Discontinued)